labcorp america lh
ep exce consensu lh ep beat
slightli lower revenu profit off-set factor
line lh initi ep guidanc vs
consensu offer relief help instil greater convict
nt growth prospect broader investor concern follow
disappoint pre-announce ep move
reflect slightli weaker lab expect off-set
continu strength covanc better profit
share climb initi guid deliv lh share rose
guidanc ep well ahead estim midpoint
par consensu despit continu lab unit challeng
 pama contract headwind view well-
document cro book strength impress testament
diversif effort continu robust btb vs
basi consist check also encourag new
billion share repurchas author initi launchpad
phase ii initi slate gener million increment cost save
next three year focu call greater detail
guidanc cro demand walgreen
partnership prospect lead lab consolid risk includ
tighten biotech fund demand shift potenti integr
headwind government reimburs chang hospit lab competit
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
labcorp provid diagnost test inform servic
labcorp america lh
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario lh
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lh
 close
labcorp america lh
diagnost light expect cro qtrli btb impress estimate total
revenu slightli reflect previous announc
headwind referr volum contract shift weather partial
off-set cro strength lab declin vs estimate rose
organ basi excl calendar shift pama weather fx organ volum fell
rose exclud weather calendar shift albeit experi
revenu access excl food less compar
unadjust food yoy includ headwind pama covanc
bright spot organ slightli aggress assumpt
post impress ttm btb ahead estimate impli
btb estimate basi ebit margin declin bp
acquisit mix pama reserv stand million cash flow
million help fund share repurchas million
labcorp america lh
compani mention price
labcorp america lh outperform tp
